Enovis Corporation (ENOV) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Enovis Corporation (ENOV) Industrial Operations Profile

Enovis Corporation, operating in the industrial machinery sector, develops and distributes medical devices for musculoskeletal conditions. With a focus on orthopedic bracing and reconstructive joint products, Enovis serves healthcare professionals globally, offering solutions for degenerative diseases, traumatic events, and sports-related injuries. The company's products are sold under the DJO brand.

What Is the Investment Thesis for ENOV?

Enovis Corporation presents a mixed investment thesis. While the company operates in a growing market for musculoskeletal solutions, its negative profit margin of -49.9% raises concerns about profitability. A gross margin of 60.5% suggests potential for improved earnings with better cost management. Key growth catalysts include expanding its product line and increasing market penetration. However, investors should closely monitor the company's ability to achieve profitability and manage its debt. The company's beta of 1.59 indicates higher volatility compared to the market. Successful execution of strategic initiatives and improved financial performance are crucial for realizing long-term value.

Based on FMP financials and quantitative analysis

ENOV Key Highlights

Market Cap of $1.51B reflects its position as a mid-sized player in the medical technology market.

• Gross Margin of 60.5% indicates strong pricing power and efficient production processes.
• Negative Profit Margin of -49.9% highlights challenges in achieving profitability and managing expenses.
• Beta of 1.59 suggests higher volatility compared to the overall market, potentially due to growth initiatives or market sensitivity.
• No Dividend Yield reflects a focus on reinvesting earnings for growth rather than returning capital to shareholders.

Who Are ENOV's Competitors?

ENOV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ENOV's Key Strengths?

Comprehensive product portfolio for musculoskeletal conditions.

• Established DJO brand recognition.
• Extensive distribution network.
• Strong gross margin.

What Are ENOV's Weaknesses?

Negative profit margin.

• High debt levels.
• Dependence on third-party distributors.
• Exposure to regulatory changes in the medical device industry.

What Could Drive ENOV Stock Higher?

Launch of new reconstructive joint products in Q3 2026.

• Expansion of digital health solutions to enhance patient outcomes.
• Strategic acquisitions to broaden product portfolio and market reach.
• Increasing market penetration in emerging markets.

What Are the Key Risks for ENOV?

Financial-distress signal — its Altman Z-Score of -0.23 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-60.1%) — the business is not currently generating profit on shareholder capital.
• Product liability lawsuits related to medical devices.
• Economic downturns affecting healthcare spending.
• Intense competition from established medical device companies.
• Changes in reimbursement policies impacting product pricing.
• Supply chain disruptions affecting manufacturing and distribution.

What Are the Growth Opportunities for ENOV?

• Expanding Reconstructive Joint Products: Enovis can capitalize on the growing demand for joint replacement and repair solutions. The global joint reconstruction market is projected to reach $23.7 billion by 2027, driven by an aging population and increasing obesity rates. By investing in research and development to enhance its hip, knee, shoulder, and other joint products, Enovis can capture a larger share of this expanding market. Timeline: Ongoing.
• Increasing Market Penetration in Emerging Markets: Emerging markets present significant growth opportunities due to increasing healthcare spending and rising awareness of advanced medical technologies. By expanding its distribution network and tailoring its product offerings to meet the specific needs of these markets, Enovis can drive revenue growth and establish a stronger global presence. Focus on regions like Asia-Pacific and Latin America. Timeline: Ongoing.
• Leveraging Digital Health Solutions: Integrating digital health technologies, such as wearable sensors and remote monitoring devices, can enhance patient outcomes and improve the efficiency of healthcare delivery. By developing and offering digital health solutions that complement its existing product portfolio, Enovis can differentiate itself from competitors and attract new customers. The digital health market is expected to reach $660 billion by 2027. Timeline: Upcoming.
• Strategic Acquisitions to Expand Product Portfolio: Pursuing strategic acquisitions of complementary businesses can enable Enovis to expand its product portfolio and enter new market segments. By acquiring companies with innovative technologies or established market positions, Enovis can accelerate its growth and enhance its competitive advantage. Focus on companies specializing in sports medicine, pain management, and rehabilitation. Timeline: Ongoing.
• Enhancing Direct-to-Consumer Sales Channels: Strengthening its direct-to-consumer (DTC) sales channels can enable Enovis to reach a broader customer base and improve its brand visibility. By investing in e-commerce platforms and digital marketing initiatives, Enovis can increase its DTC sales and reduce its reliance on traditional distribution channels. The global e-commerce market is projected to reach $6.2 trillion in 2026. Timeline: Ongoing.

What Are ENOV's Competitive Advantages?

• Established DJO brand recognition.
• Comprehensive product portfolio covering a wide range of musculoskeletal conditions.
• Extensive distribution network including independent distributors and direct sales.
• Proprietary technologies and intellectual property in medical device design and manufacturing.

What Does ENOV Do?

Enovis Corporation, formerly known as Colfax Corporation, is a global medical technology company dedicated to developing, manufacturing, and distributing medical device products. Founded with a vision to improve patient outcomes in musculoskeletal care, Enovis has evolved into a key player in the orthopedic and pain management sectors. The company's comprehensive portfolio includes rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems, compression garments, therapeutic shoes and inserts, and electrical stimulators for pain management. Additionally, Enovis offers a range of reconstructive joint products targeting the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis distributes its products through a diverse network, including independent distributors, healthcare professionals, consumer retail stores, and pharmacies. The company also sells directly to customers under its well-known DJO brand. Headquartered in Wilmington, Delaware, Enovis continues to innovate and expand its product offerings to meet the evolving needs of orthopedic specialists, surgeons, primary care physicians, physical therapists, and other healthcare providers worldwide. The company's commitment to quality and patient care has solidified its position as a trusted partner in the medical technology industry.

What Products and Services Does ENOV Offer?

• Develops rigid and soft orthopedic bracings.
• Manufactures hot and cold therapy products.
• Offers bone growth stimulators.
• Provides vascular therapy systems and compression garments.
• Produces therapeutic shoes and inserts.
• Creates electrical stimulators for pain management.
• Offers reconstructive joint products for hip, knee, shoulder, and other joints.

How Does ENOV Make Money?

• Develops and manufactures medical devices for musculoskeletal conditions.
• Sells products through independent distributors, healthcare professionals, and retail stores.
• Markets products directly to consumers under the DJO brand.
• Generates revenue through product sales and related services.

What Industry Does ENOV Operate In?

Enovis Corporation operates within the industrial machinery sector, specifically focusing on medical devices for musculoskeletal conditions. The market is driven by an aging population, increasing prevalence of sports-related injuries, and advancements in orthopedic technology. Competition includes companies like IDEX Corporation (IEX), ITT Inc. (ITT), and Donaldson Company, Inc. (DCI), each with varying focuses within the broader industrial space. Enovis differentiates itself through its comprehensive product portfolio and established DJO brand, positioning it to capitalize on the growing demand for orthopedic and pain management solutions.

Who Are ENOV's Key Customers?

• Orthopedic specialists
• Surgeons
• Primary care physicians
• Physical therapists
• Patients with musculoskeletal conditions

Company Profile

Enovis Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Wilmington, US. The company is led by CEO Damien McDonald. ENOV has traded publicly since 2008.

Enovis Corporation Financial Trajectory

Enovis Corporation (ENOV) reported $582.8M in revenue for Q3 2026, a decline of 1.1% compared to the prior quarter. The company recorded a net loss of $1.2M, with diluted EPS of $-0.02. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Industrials. Across the four most recent quarters, ENOV averaged $-4.85 in diluted EPS.

How Enovis Corporation Is Valued

Enovis Corporation carries a market capitalization of $1.51B, placing it in the small-cap category. Relative to its peer group, ENOV's quantitative score of 17/100 is below the peer average of 67/100.

Return on equity for Enovis Corporation stands at -60.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -29.7%, showing how much profit it generates from its asset base. Its free cash flow yield is 3.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.04 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -96.7%, the inverse of the P/E and a quick read on earnings relative to price.

Enovis Corporation's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -0.23 places it in the distress zone, a signal of elevated financial risk.

Enovis Corporation has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 10.3% above estimates on average.

Wall Street analysts project Enovis Corporation revenue of about $2.34B for fiscal 2026, with EPS near $3.64. The estimate reflects 9 contributing analysts.

ENOV Financials

ENOV Latest News

ENOV Analyst Consensus

ENOV MoonshotScore

Common Questions About ENOV (Industrials)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources